These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29943351)

  • 1. Lights and shadows of long-term dual antiplatelet therapy in "real life" clinical scenarios.
    Scherillo M; Cirillo P; Formigli D; Bonzani G; Calabrò P; Capogrosso P; Caso P; Esposito G; Farina R; Golino P; Lanzillo T; Mascia F; Mauro C; Piscione F; Sibilio G; Tuccillo B; Villari B; Trimarco B
    J Thromb Thrombolysis; 2018 Nov; 46(4):559-569. PubMed ID: 29943351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International patterns of dual antiplatelet therapy duration after acute coronary syndromes.
    Bueno H; Pocock S; Danchin N; Annemans L; Gregson J; Medina J; Van de Werf F
    Heart; 2017 Jan; 103(2):132-138. PubMed ID: 27504002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
    Varenhorst C; Jensevik K; Jernberg T; Sundström A; Hasvold P; Held C; Lagerqvist B; James S
    Eur Heart J; 2014 Apr; 35(15):969-78. PubMed ID: 24122961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term dual antiplatelet therapy: pharmacological and clinical implications.
    Di Mario C; Mugelli A; Perrone Filardi P; Rosano G; Rossi F
    J Cardiovasc Med (Hagerstown); 2018 Aug; 19(8):399-410. PubMed ID: 29894353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy].
    Massberg S; Polzin A
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1090-1093. PubMed ID: 30060279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple Therapy Versus Dual Antiplatelet Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndromes: A Systematic Literature Review.
    Fake A; Ranchord A; Harding S; Larsen P
    Curr Cardiol Rev; 2017; 13(4):325-333. PubMed ID: 28969538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High platelet reactivity--the challenge of prolonged anticoagulation therapy after ACS.
    Brouwer MA; Jaspers Focks J; Verheugt FW
    Thromb Haemost; 2013 May; 109(5):799-807. PubMed ID: 23426079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
    Roe MT; Cyr DD; Eckart D; Schulte PJ; Morse MA; Blackwell KL; Ready NE; Zafar SY; Beaven AW; Strickler JH; Onken JE; Winters KJ; Houterloot L; Zamoryakhin D; Wiviott SD; White HD; Prabhakaran D; Fox KA; Armstrong PW; Ohman EM;
    Eur Heart J; 2016 Jan; 37(4):412-22. PubMed ID: 26637834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
    Barillà F; Pelliccia F; Borzi M; Camici P; Cas LD; Di Biase M; Indolfi C; Mercuro G; Montemurro V; Padeletti L; Filardi PP; Vizza CD; Romeo F;
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18(1):1-9. PubMed ID: 27635937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.
    Bomb R; Oliphant CS; Khouzam RN
    Am J Cardiol; 2015 Jul; 116(1):148-54. PubMed ID: 25933730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
    Christodoulidis G; Baber U; Mehran R
    Curr Opin Cardiol; 2014 Jul; 29(4):301-6. PubMed ID: 24842783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which long-term antiplatelet regimen for patients with acute coronary syndromes?
    Picchi A; Ferlini M; Limbruno U; De Servi S
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):333-8. PubMed ID: 27192996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
    Garg P; Galper BZ; Cohen DJ; Yeh RW; Mauri L
    Am Heart J; 2015 Feb; 169(2):222-233.e5. PubMed ID: 25641531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.